All In Biotech

Drug Trial Radar · NCT05726786

The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)

The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy - A Multicenter Randomized Controlled Trial (INCyst Trial)

Last checked: Nov 20, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 232 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

232

Planned (sponsor's estimate)

Start

Apr 10, 2023

Primary completion

Aug 2026

Study completion Oct 2026

Sponsor

Lead sponsor
Centre Hospitalier Universitaire VaudoisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Insel Gruppe AG, University Hospital Bern; Hôpital Riviera-Chablais, Vaud-Valais; University Hospital, Geneva
First posted
Feb 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial research study is to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing a cystectomy. As a secondary focus, this study will aim to develop a signature that would identify patients that would benefit the most from IN. This is a multicentric (Swiss: N=3), prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers.

Conditions

  • Bladder Cancer
  • Interstitial Cystitis
  • Painful Bladder Syndrome
  • Neurogenic Bladder
  • Hemorrhagic Cystitis
  • Endometriosis
  • Bladder Disease

Interventions

  • ImmunonutritionDrug

    Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland. IN will be administered as per manufacturer suggestion, i.e. three times a day during 7 days preoperatively. Oral Impact® is a powdered oral feed that provides 309 kcal/bag

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Infectious complication after cystectomyTime frame: 30-days afetr surgery

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospital of Bern

    Bern, Switzerland · Recruiting

  • University Hospital of Geneva

    Geneva, Switzerland · Recruiting

  • Hospital of Riviera-Chablais

    Rennaz, Switzerland · Recruiting

  • Centre Hospitalier Universitaire Vaudois, CHUV

    Lausanne, Canton of Vaud, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.